Knoll L D, Benson R C, Bilhartz D L, Minich P J, Furlow W L
Center for Urological Treatment and Research, Nashville, Tennessee, USA.
J Urol. 1996 Jan;155(1):144-6. doi: 10.1097/00005392-199601000-00055.
We evaluated the efficacy and safety of yohimbine and isoxsuprine or pentoxifylline in the management of vasculogenic erectile dysfunction.
A total of 20 patients diagnosed with arterial insufficiency and cavernous venous leakage by pharmacological penile duplex scanning underwent nonhormonal oral therapy. A randomized crossover study was performed using 5.4 mg. yohimbine plus 10 mg. isoxsuprine or 400 mg. pentoxifylline 3 times daily. Response to therapy was assessed by a sexual questionnaire and repeat penile duplex ultrasonography.
No patient in either phase of the study in either group had a complete response to the oral regimen(s) and there was no improvement in the pre-injection or post-injection cavernous arterial peak systolic flow velocities or resistance indexes.
Our study suggests that these oral agents, although well tolerated, were not effective in the management of these patients with mixed vasculogenic erectile dysfunction.
我们评估了育亨宾与异克舒令或己酮可可碱治疗血管性勃起功能障碍的疗效及安全性。
通过阴茎药物双功能扫描诊断为动脉供血不足和海绵体静脉漏的20例患者接受了非激素口服治疗。采用随机交叉研究，每日3次服用5.4毫克育亨宾加10毫克异克舒令或400毫克己酮可可碱。通过性调查问卷和重复阴茎双功能超声检查评估治疗反应。
两组研究的任何阶段均无患者对口服治疗方案完全有效，注射前或注射后海绵体动脉收缩期峰值流速或阻力指数均无改善。
我们的研究表明，这些口服药物虽然耐受性良好，但对这些混合型血管性勃起功能障碍患者的治疗无效。
